A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Ozagrel (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Kissei Pharmaceutical
- 24 Apr 2017 According to a company media release, since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug, Kissei cautiously discussed a future development policy with Teika and has decided to discontinue the development of this drug.
- 24 Apr 2017 Status changed from recruiting to discontinued, according to a Kissei Pharmaceuticals media release.
- 22 Jul 2015 New trial record